Seamlessly connecting healthcare providers with the supplies they need since 1976

2024 Flu Season

IS YOUR PRACTICE PREPARED?

Privately administered influenza vaccines are FREE until 30th of September 2024, for all 6 month and older Queenslanders. This program from QLD Health will reimburse Vaccination Service Providers (VSPs) for privately purchased vaccines administered to Queenslanders not eligible under the National Immunisation Program (NIP).

Vaccines should continue to be ordered through your usual process.

Vaccination providers will be able to seek reimbursement from Queensland Health for all brands of privately purchased influenza vaccines. There will be a fixed rate reimbursement fee of $25 (ex GST) for each privately-purchased administered influenza vaccine during the life of the Program, covering the cost of the vaccine and the administration.

Please note: any remaining/unadministered stock from the current season will not be reimbursed.

Learn about advancements in Influenza Vaccine Technology through this free Health Ed for Nurses short course online now!

Infectious Disease Physician and Clinical Microbiologist, A/Prof Paul Griffin, explains Australia’s advances in influenza vaccine technology, as well as the differences between influenza vaccines and why this is important to understand in order to better inform patients of the choices available.

Click here to access now!

The WHO recommends that trivalent vaccines for use in the 2024 southern hemisphere influenza season contain the following: 

Egg-based vaccines

  • an A/Victoria/4897/2022 (H1N1)pdm09-like virus;
  • an A/Thailand/8/2022 (H3N2)-like virus; and
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

  • an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;
  • an A/Massachusetts/18/2022 (H3N2)-like virus; and
  • a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in 2024 southern hemisphere influenza season, the WHO recommends inclusion of the following B/Yamagata lineage component:

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

Products to compare:
Comparing Products